Impax cleared to market Intuniv generic
HAYWARD, Calif. — Impax Laboratories Inc. has received approval from the Food and Drug Administration for guanfacine extended-release tablets, a treatment for attention deficit hyperactivity disorder (ADHD). Impax said late Wednesday that its guanfacine ER product, a generic version of Intuniv from Shire, comes in strengths of 1 mg, 2 mg, 3 mg and 4
